Industry Webinar: A New Dawn for IgA Nephropathy – Redefining What is Possible With Sparsentan

  • Register
    • Non-member - Free!
    • Member - Free!
    • Subscriber - Free!
    • Free trial - Free!

KDIGO draft guidelines recommend that proteinuria, the only validated biomarker for disease progression in IgAN, be maintained at <0.5 g/d (preferably <0.3 g/d) to reduce the rate of kidney function loss to <1 ml/min/y. In the PROTECT phase 3 study, sparsentan reduced proteinuria and increased the proportion of pts achieving proteinuria of <0.5 or <0.3 g/d. Post-hoc analyses showed that achieving low proteinuria was predictive of better long-term kidney function, and pts once considered low risk (UPCR < 1.0 g/g) also benefited from these proteinuria reductions. Similar proteinuria reductions were observed in treatment naïve pts in the interim analyses of the phase 2 SPARTAN trial. As nephrologists consider the evolving treatment landscape and guidance, foundational nephroprotective therapies will be key to reducing proteinuria and preserving kidney function.

Learning objectives: 

  • Describe the draft KDIGO criteria for risk of disease progression in IgAN, the proposed target proteinuria levels for preserving kidney function, and the scientific rationale for these proposed proteinuria targets
  • Describe the clinical benefits of achieving proteinuria remission and how sparsentan helps clinicians achieve these targets
  • Evaluate the evolving IgAN therapeutic landscape and where sparsentan fits into treatment in order to achieve proteinuria remission and reduce nephron loss

Further reading:

Sydney Tang

Hong Kong

Nasim Wiegley

USA

Key:

Complete
Failed
Available
Locked
Industry Webinar: A New Dawn for IgA Nephropathy – Redefining What is Possible With Sparsentan
Open to view video.
Open to view video.